Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

Introduction : Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much l...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
Formato: Artigo
Idioma:Inglês
Publicado: Termedia Publishing House 2016-12-01
Series:Gastroenterology Review
Assuntos:
adalimumab
deep remission
mucosal healing
Crohn’s disease
Acceso en liña:https://www.termedia.pl/Adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-Crohn-s-disease,41,28947,1,1.html
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares